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INTRODUCTION
Age-related macular degeneration (AMD) is a
degenerative maculardisordermostoftenclinically
apparent after 50 years of age, characterized by
certain fundal features and after exclusion ofother
disorders e.g. highmyopia etc. Drusen (deposits of
extracellularmateriallyingbetweenretinalpigment
epithelium(RPE)andtheinnercollagenous zoneof
Bruch's membrane -Figure 1), hyperpigmentation
andhypopigmentationoftheRPE,withoutvisibility
ofchoroidal blood vessels are regarded as features
of early AMD. Although drusen are the hallmark
ofAMD one or more hard drusen were found in at
least 95% ofthe aged populations assessed in the
larger Caucasian studies with small hard drusen
being the most common in all age groups. The two
stages oflate AMD include exudative/neovascular
(wet) and non-exudative/geographic atrophy, GA
(dry) with an 80:20 ratio being observed in the
majority of AMD prevalence studies (Figures 2
and 3 respectively). Exudative AMD, which is
characterised by choroidal neovascularization and
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Fig 1. Interface between retinal pigment epithelium and
Bruch's membrane demonstrating drusen location.
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Fig 2. Retinal stereoscopic fundal photograph illustrating
the features ofwetAMD.
Fig 3. Retinal stereoscopic fundal photograph illustrating
the features ofdryAMD.
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fibrous scarring of the macula, is responsible for
80% oftheAMD-related blindness.
AMD is the leading (54.4%) cause ofblindness in
Caucasians, compared to only 4.4% and 14.3% of
cases in black and Hispanic persons, respectively.'
Theprevalence (1.6%2) andincidence oflateAMD
(1.1% over five years3), in association with the
increasing longevity of populations, is impacting
significantly on patients, their carers and National
Health Service.AMD affects420,000people inthe
UnitedKingdomwithanestimated214,000people
having registrable visual impairment secondary to
AMD.4Apartfromthemoreobviousdisablingeffects
ofAMD associated with loss of central vision, a
frequently overlooked effect is depression (33% of
affected individuals), which becomes particularly
high on involvement ofthe second eye.5
Ageisthemostconsistentandsignificantassociation
with AMD and related lesions and is widely
supportedinpopulation-basedAMDprevalenceand
epidemiology studies, irrespective ofethnic/racial
background.2 This increase is less significant for
non-white groups. A steep rise in prevalence rates
ofearly and late AMD occur in the .70years.
Although numerous studies have failed to detect a
significant gender difference in the prevalence of
earlyorlateAMD, femalesappeartohaveaslightly
increased risk ofdeveloping lateAMD.2
AMD is a multifactorial disease involving the
interaction of genetic and environmental factors.
Difficulties in classification of AMD phenotype
continues to beproblematic with anegative impact
on unravelling the complex genetic aetiology.
HISTORICAL BACKGROUND
Hutchinson andTayin 1875 wereprobablythe first
ophthalmologistsintheEnglishliteraturetodescribe
whatispresentlycalledAMD, whentheydescribed
the symmetrical fundal changes in senile patients.
It was not until 1885 thatAMD was recognized as
a discrete clinical entity by Otto Haab and called
"senile macular degeneration (SMD)". This term
has been extensively used through the generations
by ophthalmologists to describe the very common
macular changes observed in the elderly. Various
nameshavebeenusedovertheyearsforSMD,6with
age-related maculopathy (ARM) and AMD being
the interchangeable terms used today.
AMD has been difficult to classify and until
recently a lack ofstandard classification has made
it difficult to compare and review progress in the
research field. The publication of an international
classification and grading system for ARM and
AMDin 1995,7basedonthemorphologicalchanges
observedonstereoscopic(30°or350)colourfundus
transparenciesinindividuals.50yearshasfacilitated
this to a certain extent. This system is based on the
Wisconsinagerelatedmaculopathygradingsystem
with the macula area being defined by a standard
grid facilitating the locations and measurements
ofthe previously mentioned AMD features 8 (refer
Figure 4). Although this was the first standardised
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Classification ofmutually exclusive stages ofAMD takenfrom van Leeuwen et al, 2003
Stage Definition
Oa No signs ofAMD
Ob Hard drusen (< 63gm) only
1a Soft distinct drusen (. 63gm) only
lb Pigmentary abnormalities only, no soft drusen (. 63gm)
2a Soft indistinct drusen (. 125gm) or reticular drusen only
2b Soft distinct drusen (. 63gm) withpigmentary abnormalities
3 Soft indistinct (. 125gm) or reticular drusen with pigmentary abnormalities
4 Atrophic or neovascularAMD
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Fig 4. Standard retinal fundus grid for classification and
grading ofAMD.
classification andgrading system forAMD, a more
practicalAMDphenotyping systemwith"affected"
AMD statusbeing designated as stage > 2ai.e. soft
indistinctdrusen(. 125gm) orreticulardrusen was
developed recently (Table 1).9
GENETICS
Evidence of the genetic basis to AMD is well
established as a result of many different types of
studies over the preceding twenty years.
Case reports ofconcordance forAMD phenotypes
within monozygotic twin pairs were perhaps the
earliest indication ofa genetic basis forAMD.'0
Numeroustwinstudieshavesignificantlysupported
the genetic component ofAMD II with late AMD
having a higher heritability (quantitative measure
of innate genetic predisposition to a disease) in
additionto amoderatetolargeuniqueenvironmental
component in the largest twin study involving 840
elderly male twins.'2
Familialaggregationstudieshavealsodemonstrated
the genetic component toAMD with alifetime risk
ratio of4.2 for late AMD in relatives.'3
Loci on chromosomes 1q31 and 10q26 have been
consistently identified inAMD genome wide scans
and supports the hypothesis of genes within these
loci contributing to AMD.14-15
The first disease locus for non-exudative AMD,
(gene symbol ARMD1),16 on chromosome 1q25-
31 was discovered in a multigenerational pedigree
in which ten members were affected with non-
exudative /dry AMD. Subsequently a Gln5345Arg
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mutation in the gene Hemicentin-1 was shown to
segregatewiththisAMDphenotype. 7Hemicentin-
1 (also known as Fibulin 6/FBNL6), a member of
the fibulinprotein family, encodes forextracellular
matrix proteins with a potential role in drusen
formation and therefore AMD pathogenesis.
However, mutations inHemicentin-1 havenotbeen
found to be associated with AMD in three other
separate studies.5'18-19 Although support for the
ARMD1 locus, is substantial in the genome wide
scans, it seems likely that another gene other than
Hemicentin-1 may be responsible.
The firstputative disease locus for exudativeAMD
was detected between 17-19.35 megabases (Mb)
on chromosome 16pl2-13 using familial linkage
in a large Northern Irish pedigree.20 The familial
mutation remains undetected. Association studies
in a case-control study of sporadic AMD cases
from Northern Ireland added slight support to this
identified linkage region.20
Threeothergenes,Fibulin5,APOEandComplement
Factor H have been reported to be associated with
AMD phenotypes.
Missense mutations in the Fibulin 5 gene were
foundin 1.7% of402 patients withAMD inacase-
control study.2' Further studies analyzing fibulin 5
are required in order to verify the significance of
this. Fibulin 5 is a candidate gene for AMD due
to its role in extracellular matrix proteins and in
particular the polymerization ofelastin which is a
majorcomponentofBruch'smembraneandinvolved
inAMD pathogenesis.
ThereissubstantialevidencetoshowthattheAPOE
c4 allele has a protective effect with AMD, while
APOEe2alleleisassociatedwithamodestincrease
in risk ofexudative AMD.22 APOE is a functional
candidate gene due to its role inlipidtransport and
distribution, involvement in drusen formation and
high expression levels in the retina. The opposite
effectofAPOEinAMDtoitsroleincoronaryheart
disease remains unexplained at present.
Recently a 2.45-5.57 increased risk forAMD with
a Tyr4O2His polymorphism in the gene encoding
ComplementFactorH (CFH) hasbeenreportedby
independentresearchgroups,althoughtheexistence
ofother coding or splice site variants within CFH
that may modulate the AMD risk could not be
excluded .23-26 CFH is involved in the complement
pathwayandinparticularimpactsonC3 convertase
enzyme. Evidence fordeposition ofcomponents of
www.ums.ac.uk
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this complement pathway in drusen and choroid of
eyes withAMD is extensive. 27'60-61
Despite the phenotypic similarities between the
hereditary monogenic macular dystrophies and
AMD e.g. Best disease, with the exception of
ABCA4, none of the causative genes was found
to be responsible for a significant percentage of
AMD cases. The ABCA4 screening consortium28
assigned a threefold and fivefold risk ofAMD in
D2177NandG1961EABCA4carriersrespectively,
howeverreplication ofthese findings havenotbeen
possible, leading to much controversy surrounding
itspotentialroleinAMD.Theobservationthatsome
inheritedmaculardystrophiesmayhavewidespread
retinal dysfunction, and the possibility of several
genes acting synergistically or being ubiquitous,
are among the suggestions by Michaelides et al,
200329 for the non-significant role ofthese genes
in the genetic predisposition toAMD.
Theabovestudieshaveclearlyestablishedthatgenetic
predispositionplays amajorroleintheaetiologyof
AMD. Despite this, genetics ofAMD are regarded
ascomplexwiththepossible involvementofone or
moregenesenhancinganindividual'ssusceptibility
for developing the condition. The possibility that
there may be other genes that modify the age of
onset or phenotypic features ofAMD has also to
be considered. These genes may act independently
or in conjunction with environmental factors e.g.
smoking.
Genetic studies ofAMD involve consideration of
the clinical heterogeneity associated with AMD
and correlation with genetic heterogeneity i.e. dry
andwetAMD mayhave differentgenetic aetiology
and specific phenotypes within AMD pedigrees
may run true within families.30 The recent surge in
genetic studiesfrom2000withnineAMDgenome-
wide screens published within the last eighteen
months maybeattributed tothegrowing awareness
of genetics in a number of other complex late-
onset medical disorders e.g. Alzheimer's disease.
Unravelling the genetics of AMD will facilitate
the possible expansion of the knowledge of the
pathophysiology ofAMD, identification of at risk
individuals prior to the onset of clinical findings,
and the development ofpreventive treatments and
therapeutic strategies.
NON-GENETIC RISK FACTORS
In addition to age, gender and race/ethnicity, there
are several other risk factors which have been
implicated in AMD.
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Evidence for a significant association between
smoking and late AMD is extensively provided in
numeroustypesofstudies.3 1-32Currentsmokershad
thehighestriskofAMDcomparedtoex-smokersor
non-smokersacrossallstudies.Thiswasparticularly
highlightedinthemeta-analysisofthreeprospective
studies,32theassociationwithcurrentsmokingbeing
stronger with exudative AMD (OR=4.55, 95% CI,
2.74-7.54)thanwithnon-exudativeAMD (OR=2.56,
95%CI, 1.26-5.2). In addition, current smokers
had about a 2.5 fold increased risk of developing
AMD33-34andweremorelikelytoshowprogression
of early AMD (RR=1.34, 95% CI, 0.94-1.91), to
develop pigmentary abnormalities (RR=1.32, 95%
CI, 0.89-1.98) and large soft drusen (.250,um)
(RR=2.19, 95% CI, 1.44-3.32) than ex smokers.35
A significantly earlier age ofdevelopingAMD (67
years) in current smokers than in ex (73years) or
never smokers (77years) was detected in the Blue
Mountain Eye Study population.36 In addition a
trend for increased risk ofAMD with increasing
number of smoking pack years, with the risk of
AMD remaining increased until at least 20 years
aftersmokingcessationwasobserved .34Thecausal
relationshipofsmokingwithAMDcanbeexplained
byitsrecognisedabilityto increase oxidative stress
either directly or indirectly with lowering dietary
intakeofvitaminCandB-carotene,andtheassociated
lower macular pigment density.
Population-based incidence studies have provided
useful predictors of progression to AMD which
include soft distinct/indistinct (. 125-250m)
and reticular drusen and hyperpigmentation.9 37-38
Additional AMD risk factors highlighted by these
studies included .10% macular area involved by
drusen, > 5-10 drusen and depigmentation. Two
of these studies, demonstrated an increased risk
between3-11 foldoflargeareasofsmallharddrusen
developing into large (2125,um) drusen.3738
A J-shaped relationship between body mass index
(BMI)andAMDdevelopmentandrateofprogression
has been illustrated with the leanest (BMI< 22)
and particularly the obese (BMI>30) being at
significantly increased risk.31
Although evidence is conflicting, there may be an
associationwithhyperopiawithAMD,albeitminor,
which would alert ophthalmologists to this slightly
increased risk group of individuals. There is no
hypothesis for this association at present.
Itwouldappearthatcataract,particularlythenuclear
type, is associated with a moderate risk of early
AMD.31 Although cataract surgery can exacerbate
www.ums.ac.uk
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AMD39removal ofthe cataract improves qualityof
life and visual function improvement even in end-
stage disease.40 The association of AMD in eyes
that have undergone cataract surgery may be due
tobetterdetection secondarytoeasiervisualisation
ofthe fundus, the increased risk ofphotic retinal
damage fromthe lights ofoperating microscopes 41
and lastly the possible inflammatory changes post
cataractsurgerythatmaypredisposetotheincreased
exudativeAMD risk.39
Assessment of the relationship of light exposure
andAMD has been fraught with many difficulties.
HoweversunlightexposureappearstoincreaseAMD
risk,butultimatelythismaybethroughtheincreased
incidenceandprogressionofearlyAMDandrelated
lesionsi.e.softindistinctdrusenandretinalpigment.
Advice aboutprotective gearandlengthofsunlight
exposure may help reduce this risk.
A significant numberofstudies have demonstrated
aweakassociationbetweenhypertensionandAMD
which may be attributed to the various methods
and definitions used.3 1-32 Overwhelming evidence
doesnotsupportanassociationwithcardiovascular
disease andAMDprevalence 32,43 anddevelopment
and progression despite some common risk
factors.44
Dietaryfatintakemayinfluencetheriskofdeveloping
AMDbypredisposingtoatherosclerosisandaltering
the composition ofBruch's membrane rendering it
less permeable to diffusion ofnutrients and waste
products to andfromthe RPE.45-46 Inaddition there
isaprotectiveassociation(OR=0.52,95%CI,0.22-
1.24)betweenhigherfishconsumptionandAMD.46
Thereissufficientevidencethereforetorecommend
dietary alterations inthose individuals withmildto
moderate signs ofAMDtoreduceprogressionwith
the added benefit to the cardiovascular system.
The effect ofstatins in AMD remains unresolved-
with some studies reporting an inverse relationship
between statins and AMD i.e. protective with
individuals taking statins having a 1/11 risk of
AMD47 but unsupported in other studies.48
There are conflicting reports ofthe effect and type
of alcohol consumption on the development of
AMD.49-50Thedifferentrelationshipsthathavebeen
identified betweenAMD and types ofalcohol may
be indicative ofdietary (antioxidants) or life style
factors e.g. smoking has been strongly associated
with heavy drinking50 or alcohol consumption
patterns ofdifferent populations studied.
PATHOGENESIS OFAMD
Physiological ageing in humans is a generalised
processassociatedwithcumulativeoxidativestress.
The retina and RPE are particularly susceptible to
oxidativestressduetotheirhighoxygenconsumption
and levels of cumulative irradiation exposure in
additiontoproportionofpolyunsaturatedfattyacids
and chromophores.51
Oxidative stress is the most likely primary event
inAMD pathogenesis, in addition to inflammation
andangiogenesis onthebackgroundofgenetic and
environmental influences as depicted in Figure 5.
Evidence for the role of inflammation in AMD
is extensive and is inclusive of anatomical52 and
molecularstudiesandmorerecentlyanimalmodels.53
However, it is largely the molecular studies that
havecontributedtothecurrentunderstandingofthe
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Figure 5 Ageing versus AMD (Taken from Zarbin MA, 200427)
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TABLE II
Major molecular constituents ofdrusen (from Zarbin et al, 200427)
a1 Antichymotrypsin
ai Antitrypsin
Alzheimer amyloid B peptide
Advanced glycation end products
Amyloid P component
Apolipoproteins B and E
Carbohydrate moieties recognisedbywheatgermagglutinin, Limaxflavus agglutinin, concanavalin
A, Arachis hypogaea agglutinin, and Ricinis communis agglutinin
Cholesterol esters
Clusterin
Complement factors (Clq, C3c, C4, C5, C5b-9 complex)
Cluster differentiation antigen
Complement receptor 1
Factor X
Heparin sulphate proteoglycan
Human leucocyte antigen DR
Immunoglobulin light chains
Majorhistocompatibility complex class II antigens
Membrane cofactor protein
Peroxidized lipids (derived from long-chain polyunsaturated fatty acids ie. linolenic acid and
docosahexanoic acid, which are usually found inphotoreceptor outer segments)
Phospholipids and neutral lipids
Tissue inhibitor ofmatrix metalloproteinases-3
Transthyretin (major carrier ofvitaminA in the blood)
Ubiquitin
Vitronectin
© The Ulster Medical Society, 2005. www.ums.ac.uk
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Figure 6 Angiogenesis in choroidal nevascularisation (TakenfromAmbatietal200353)
inflammatoryrole inAMD andthe developmentof
alocalinflammationmodelofdrusenbiogenesis.55
The extensive range ofinflammatory constituents
identified in drusen further support this (Table 2).
AMD has been postulated to represent another
chronic age-related inflammatory disease due to
the striking compositional similarities between
drusen and the deposits orplaques associated with
Alzheimer disease, atherosclerosis and glomerular
membrane disease.56-57
TheroleofangiogenesisinAMDiswelldocumented
although much remains unknown. A summary
of angiogenesis in CNV is provided in Figure 6.
CNV, which represents a non-specific response
to a specific stimulus in nearly forty ophthalmic
conditions, includingAMD is aresult ofan altered
balancebetweenproangiogenic andantiangiogenic
factors.58
AMDpathogenesishasbeenextensivelyinvestigated
in anattempttounravel the disease, howevermuch
remains unknown.
CLINICALASPECTS OFAMD
A degree ofoverlap between the two types oflate
AMD is well recognised, with both sometimes
occurring in the same eye or at once in different
eyes in the same person.
A typical history of a patient with non-exudative
AMD is ofa lengthyprocess ofgradual visual loss
interrupted by periods ofdeterioration. Sparing of
the foveal centre occurs late in the course of the
disease5 withtheprimaryvisualimpairmentarising
from scotomas (blind spots) which correspond to
geographic atrophy (GA). In the early stages of
© The Ulster Medical Society, 2005.
GA,thepatient's abilitytoreadandrecognise faces
is compromised, with the size and position ofthe
atrophicareadeterminingthelevelofimpairment.60
Sudden loss ofcentral vision in a patient with GA
mayindicatethepresenceofanexudativecomponent
or the final involvement of the central macula in
geographic atrophy.
The primary event in exudative AMD is choroidal
neovascularization (CNV), referring to the growth
of new choroidal blood vessels, usually located
beneath the RPE or rarely in the subretinal space.
CNV is usually classified by both its location
relative to the foveola i.e. subfoveal,juxtafoveal or
extrafoveal and itspattern offluorescence (classic,
occultormixed)onfluoresceinangiography(Figure
7). CNV appears as a greenish-grey lesion on
ophthalmoscopy, often accompanied by sensory
Fig 7. Fluorescein angiogram illustrating wetAMD.
www.ums.ac.uk
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retinal detachment. There may be additional signs
ofsubretinalexudateandblood.Althoughthepatient
maybeasymptomatic,themajoritycomplainofthe
suddenonsetofdistortionandlossofcentralvision.
CNV may precipitate detachment and tears in the
RPE. Fibrovasculardisciformscartissueformation
occurs with repeated leakage ofblood and serum
from the CNV, and represents the end-stage. The
degree ofRPE and photoreceptor degeneration is
proportional to the diameter and thickness ofthe
disciform scar.
TREATMENT
Treatments in AMD can be divided into the well
recognised categories ofpreventative, established
and innovative.
Lifestyle changes demonstrated to be beneficial
in reducing occurrence and progression ofAMD
includecessationofsmokingandantioxidantvitamin
and mineral supplementation. A modest benefit of
antioxidantvitaminandmineralsupplementationin
people with moderate to severe signs ofAMD was
the conclusion ofthe Cochrane review.6" However
it has been shown that individuals without AMD
could not delay or prevent the onset ofdisease by
takingantioxidantandmineralsupplements.62Other
lifestyle factors such as more exercise, alteration
in type and amount of alcohol consumed, use of
sun protective measures and a diet ofregular fish
consumption, lowtotalandalteredfatdietaryintake
awaitfurtherresearchpriortoanyrecommendations.
Screening using the Amsler grid facilitates early
detectionofchoroidalneovascularisationAMDsigns
inthepatientwithpre-existing diseaseparticularly
in the other eye and can as such be regarded as
preventative.
Presentlythefive-yearresultsoftheComplicationsof
Age-relatedMacularDegenerationPreventionTrial,
evaluatingtheeffectoflow-intensitylasertreatment
asprophylaxis inhigh-riskpatients withnumerous
large drusen inboth eyes is eagerly awaited.
Presentlythere is no established treatment fornon-
exudative AMD.
Laser photocoagulation is a well-established and
widelyacceptedtreatmentforCNV,largelyasaresult
of the Macular Photocoagulation Studies.63 This
treatment is only beneficial when the CNV lesion
is well demarcated and located in the juxtafoveal
or extrafoveal regions, although small subfoveal
lesions may benefit. Approximately 10-15% of
patients with exudative AMD are eligible for this
treatment. Despite persistent and recurrent CNV
C The Ulster Medical Society, 2005.
in over 50% oflaser-treated eyes within 3-5 years
oftreatment,63 laserphotocoagulation continues to
remain the standard ofcare forthese lesions.
Photodynamic therapy (PDT) with verteporfin has
recentlybeenacknowledgedasanapprovedtreatment
forclassicsubfovealCNV.M4NICEguidelinesprovide
eligibilitycriteriaforNHS fundedPDT.65There are
anumberofadvantagestoPDT,includingtheability
to treat subfoveal lesions due to less destruction
of the retina compared to conventional laser
photocoagulation, andminimalocularandsystemic
sideeffects.However,atbestPDTseemstostabilize
vision. The high persistence and recurrence rate
following PDT leads to multiple repeattreatments,
and adds to the cost oftreatment.
Numerousexperimentaltherapeuticinterventionsare
underinvestigationincludingsurgicalintervention,
anti-angiogenicandangiostaticagents,transpupillary
thermotherapyandgenetherapy.Todateuntilfurther
large scale, controlled clinical trials have been
completed no consensus of the risks and benefits
ofsuch treatments can be reached.
CONCLUSIONS
AMD is the leading cause ofblindness in elderly
Caucasians,impactingsignificantlyonpatients,their
carers and National Health Service. Treatment is
limitedmainlytoreducingthe diseaseprogression.
The multifactorial aspect of AMD is well
established with age, smoking and genetics being
themostconsistentassociations. The difficulties of
phenotyping AMD have been well recognised for
manyyears andmayexplainthe limitedprogress in
identifyingtheunderlyingcomplexgeneticaetiology.
Presently the debate continues as to whether non-
exudative AMD is a separate disease and perhaps
a different aetiology to exudativeAMD orwhether
theybothrepresentacontinuous spectrumofAMD
i.e. clinical heterogeneity. However drusen size of
>125pmappearstobethemostdiscriminatingfeature
inAMD phenotyping forprogression to AMD.
AMD impinges on the practice of medical
practitioners fromvarious specialities, particularly
ophthalmology, geriatrics, psychiatry and general
practice. The recognition of the familial and
sporadic forms ofAMDbymedicalpractitioners is
paramountwiththerelevantpreventiveandscreening
interventions.
AMD was first recognized 130 years ago, however
muchremains unknown. Itwill continue topresent
a major challenge to clinicians and researchers in
the future.
www.ums.ac.uk
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